BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 28450223)

  • 21. L-alpha-aminoadipic acid restricts dopaminergic neurodegeneration and motor deficits in an inflammatory model of Parkinson's disease in male rats.
    O'Neill E; Chiara Goisis R; Haverty R; Harkin A
    J Neurosci Res; 2019 Jul; 97(7):804-816. PubMed ID: 30924171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of inflammation-related nigral degeneration and locomotor function in DJ-1(-/-) mice.
    Nguyen TA; Frank-Cannon T; Martinez TN; Ruhn KA; Marvin M; Casey B; Treviño I; Hong JJ; Goldberg MS; Tansey MG
    J Neuroinflammation; 2013 Apr; 10():50. PubMed ID: 23622116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alpha-lipoic acid improved motor function in MPTP-induced Parkinsonian mice by reducing neuroinflammation in the nigral and spinal cord.
    Zhang J; Wang M; Zhao Y; Zhang Y; Gao Y; Zhang X; Yang G
    Neurosci Lett; 2022 Jun; 781():136669. PubMed ID: 35490905
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
    Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
    J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined 1-Deoxynojirimycin and Ibuprofen Treatment Decreases Microglial Activation, Phagocytosis and Dopaminergic Degeneration in MPTP-Treated Mice.
    Costa T; Fernandez-Villalba E; Izura V; Lucas-Ochoa AM; Menezes-Filho NJ; Santana RC; de Oliveira MD; Araújo FM; Estrada C; Silva V; Costa SL; Herrero MT
    J Neuroimmune Pharmacol; 2021 Jun; 16(2):390-402. PubMed ID: 32564332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Triptolide up-regulates metabotropic glutamate receptor 5 to inhibit microglia activation in the lipopolysaccharide-induced model of Parkinson's disease.
    Huang YY; Zhang Q; Zhang JN; Zhang YN; Gu L; Yang HM; Xia N; Wang XM; Zhang H
    Brain Behav Immun; 2018 Jul; 71():93-107. PubMed ID: 29649522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tenuigenin protects dopaminergic neurons from inflammation via suppressing NLRP3 inflammasome activation in microglia.
    Fan Z; Liang Z; Yang H; Pan Y; Zheng Y; Wang X
    J Neuroinflammation; 2017 Dec; 14(1):256. PubMed ID: 29262843
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peripheral inflammation increases the deleterious effect of CNS inflammation on the nigrostriatal dopaminergic system.
    Hernández-Romero MC; Delgado-Cortés MJ; Sarmiento M; de Pablos RM; Espinosa-Oliva AM; Argüelles S; Bández MJ; Villarán RF; Mauriño R; Santiago M; Venero JL; Herrera AJ; Cano J; Machado A
    Neurotoxicology; 2012 Jun; 33(3):347-60. PubMed ID: 22330755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease.
    Gómez-Gálvez Y; Palomo-Garo C; Fernández-Ruiz J; García C
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():200-8. PubMed ID: 25863279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thrombin-induced microglial activation contributes to the degeneration of nigral dopaminergic neurons in vivo.
    Huang CF; Li G; Ma R; Sun SG; Chen JG
    Neurosci Bull; 2008 Apr; 24(2):66-72. PubMed ID: 18369384
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tanshinone IIA prevents the loss of nigrostriatal dopaminergic neurons by inhibiting NADPH oxidase and iNOS in the MPTP model of Parkinson's disease.
    Ren B; Zhang YX; Zhou HX; Sun FW; Zhang ZF; Wei Z; Zhang CY; Si DW
    J Neurol Sci; 2015 Jan; 348(1-2):142-52. PubMed ID: 25491263
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation.
    Iravani MM; Leung CC; Sadeghian M; Haddon CO; Rose S; Jenner P
    Eur J Neurosci; 2005 Jul; 22(2):317-30. PubMed ID: 16045485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apocyanin, a Microglial NADPH Oxidase Inhibitor Prevents Dopaminergic Neuronal Degeneration in Lipopolysaccharide-Induced Parkinson's Disease Model.
    Sharma N; Nehru B
    Mol Neurobiol; 2016 Jul; 53(5):3326-3337. PubMed ID: 26081143
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neurotoxic effects of lipopolysaccharide on nigral dopaminergic neurons are mediated by microglial activation, interleukin-1beta, and expression of caspase-11 in mice.
    Arai H; Furuya T; Yasuda T; Miura M; Mizuno Y; Mochizuki H
    J Biol Chem; 2004 Dec; 279(49):51647-53. PubMed ID: 15383538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostaglandin D2/J2 signaling pathway in a rat model of neuroinflammation displaying progressive parkinsonian-like pathology: potential novel therapeutic targets.
    Corwin C; Nikolopoulou A; Pan AL; Nunez-Santos M; Vallabhajosula S; Serrano P; Babich J; Figueiredo-Pereira ME
    J Neuroinflammation; 2018 Sep; 15(1):272. PubMed ID: 30236122
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of monocyte infiltration in MPTP mice reveals that microglial CX3CR1 protects against neurotoxic over-induction of monocyte-attracting CCL2 by astrocytes.
    Parillaud VR; Lornet G; Monnet Y; Privat AL; Haddad AT; Brochard V; Bekaert A; de Chanville CB; Hirsch EC; Combadière C; Hunot S; Lobsiger CS
    J Neuroinflammation; 2017 Mar; 14(1):60. PubMed ID: 28320442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-inflammatory effects of BHBA in both in vivo and in vitro Parkinson's disease models are mediated by GPR109A-dependent mechanisms.
    Fu SP; Wang JF; Xue WJ; Liu HM; Liu BR; Zeng YL; Li SN; Huang BX; Lv QK; Wang W; Liu JX
    J Neuroinflammation; 2015 Jan; 12():9. PubMed ID: 25595674
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heat shock protein 60: an endogenous inducer of dopaminergic cell death in Parkinson disease.
    Noelker C; Morel L; Osterloh A; Alvarez-Fischer D; Lescot T; Breloer M; Gold M; Oertel WH; Henze C; Michel PP; Dodel RC; Lu L; Hirsch EC; Hunot S; Hartmann A
    J Neuroinflammation; 2014 May; 11():86. PubMed ID: 24886419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transforming growth factor-β1 acts via TβR-I on microglia to protect against MPP(+)-induced dopaminergic neuronal loss.
    Liu Z; Chen HQ; Huang Y; Qiu YH; Peng YP
    Brain Behav Immun; 2016 Jan; 51():131-143. PubMed ID: 26254549
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thrombin-induced microglial activation produces degeneration of nigral dopaminergic neurons in vivo.
    Choi SH; Joe EH; Kim SU; Jin BK
    J Neurosci; 2003 Jul; 23(13):5877-86. PubMed ID: 12843292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.